Related Experiment Video
Updated: Aug 2, 2026
Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
Mumps vaccine L-Zagreb, prepared in chick fibroblasts. I. Production and field trials
M Beck1, R Welsz-Malecek, M Mesko-Prejac
1Institute of Immunology, Zagreb, Yugoslavia.
Abstract:
Leningrad-L3 Mumps Vaccine virus has been further attenuated by adaptation and passage on SPF chick embryo fibroblast cell cultures. This new mumps strain has been designated L-Zagreb and has been used to prepare mumps vaccines which meet the WHO requirements. Observations during both the field trial period prior to registration and during the later use of the vaccine showed that the few reactions observed were mild and that seroconversion was obtained in 88-98% of vaccines. The morbidity of mumps in Croatia declined more than tenfold after the introduction of the new vaccine. During a mumps epidemic, vaccine efficiency was calculated to be 97-100%.
Insights
A new mumps vaccine, L-Zagreb, derived from Leningrad-L3 Mumps Vaccine virus, shows high efficacy and safety. This vaccine significantly reduced mumps incidence in Croatia.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- The Leningrad-L3 Mumps Vaccine virus was adapted and passaged on SPF chick embryo fibroblast cell cultures.
- A novel, attenuated mumps strain, designated L-Zagreb, was developed.
Purpose of the Study:
- To develop a safe and effective mumps vaccine meeting WHO requirements.
- To evaluate the immunogenicity and efficacy of the L-Zagreb mumps vaccine.
Main Methods:
- Attenuation of Leningrad-L3 Mumps Vaccine virus through cell culture adaptation.
- Preparation of mumps vaccines using the L-Zagreb strain.
- Clinical observations and seroconversion assessments in vaccine recipients.
- Morbidity data analysis before and after vaccine introduction.
- Vaccine efficiency calculation during a mumps epidemic.
Main Results:
- The L-Zagreb mumps vaccine met WHO requirements.
- Mild reactions were observed in vaccinees, with seroconversion rates between 88-98%.
- Mumps morbidity in Croatia decreased over tenfold post-vaccine introduction.
- Vaccine efficiency during an epidemic was calculated at 97-100%.
Conclusions:
- The L-Zagreb mumps vaccine is safe and highly effective.
- The vaccine has led to a substantial reduction in mumps morbidity.
- The L-Zagreb strain represents a significant advancement in mumps prevention.
